TOXICITY AND EFFICACY OF TYROSINE KINASE INHIBITORS IN COMBINATION WITH CHEMOTHERAPY IN PATIENT WITH RESISTANT Ph-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (CASE REPORT AND LITERATURE REVIEW)

A wide range of toxic complications of BCR-ABL tyrosine kinase inhibitors therapy due to non-targeted inhibition of other protein kinases. This is of particular importance in the treatment of patients with Ph-positive lymphoblastic leukemia, who receive, in addition to tyrosine kinase inhibitors, cytotoxic drugs, enhancing myelotoxicity and, as a consequence, infections and thrombo-hemorrhagic complications. In addition, complex inter-drug interactions lead to the manifestations of combined toxicity. This article presents a case report of patient with relapsed acute Ph-positive lymphoblastic leukemia, treatment of which was accompanied by numerous complications, especially during treatment of II and III generation tyrosine kinases inhibitors.

1. Chiaretti S., Vitale A., Cazzaniga G. et al. Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. Haematologica 2013;98(11):1702–10. DOI: 10.3324/haematol.2012.080432. PMID: 23716539.

2. Thomas X., Danaïla C., Le Q.H. et. al. Long-term followup of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001;15(12):1811–22. PMID: 11753600.

3. Fielding A.K., Rowe J.M., Richards S.M. et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood 2009;113(19):4489–96. DOI: 10.1182/blood-2009-01-199380. PMID: 19244158.

4. Laport G.G., Alvarnas J.C., Palmer J.M. et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiationetoposide regimen. Blood 2008;112(3):903–9. DOI: 10.1182/blood-2008-03-143115. PMID: 18519812.

5. Druker B.J., Sawyers C.L., Kantarjian H. et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344(14):1038–42. DOI: 10.1056/NEJM200104053441402. PMID: 11287973.

6. Talpaz M., Shah N.P., Kantarjian H. et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354(24):2531–41. DOI: 10.1056/NEJMoa055229. PMID: 16775234.

7. Weisberg E., Manley P., Mestan J. et al. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006;94(12):1765–9. DOI: 10.1038/sj.bjc.6603170. PMID: 16721371.

8. O’Hare T., Shakespeare W.C., Zhu X. et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcome mutation-based resistance. Cancer Cell 2009;16(5):401–12. DOI: 10.1016/j.ccr.2009.09.028. PMID: 19878872.

9. Daver N., Thomas D., Ravandi F. et al. Final report of a phase II study of imatinib mesylate with hyper-CVAD for the frontline treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2015;100(5):653–61. DOI: 10.3324/haematol.2014.118588. PMID: 25682595.

10. Tan A.C., Vyse S., Huang P.H. Exploiting receptor tyrosine kinase co-activation for cancer therapy. Drug Discov Today 2017;22(1):72–84. DOI: 10.1016/j.drudis.2016.07.010. PMID: 27452454.

11. Soverini S., Colarossi S., Gnani A. et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006;12(24):7374–9. DOI: 10.1158/1078-0432.CCR-06-1516. PMID: 17189410.

12. Soverini S., Vitale A., Poerio A. et al. Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCRABL kinase domain mutations at low levels at the time of diagnosis. Haematologica 2011;96(4):552–7. DOI: 10.3324/haematol.2010.034173. PMID: 21193419.

13. Kantarjian H.M., Talpaz M., Giles F. et al. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann Intern Med 2006;145(12):913–23. PMID: 17179059.

14. Shah N.P., Nicoll J.M., Nagar B. et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2(2):117–25. PMID: 12204532

15. O’Hare T., Walters D.K., Stoffregen E.P. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005;65(11):4500–5. DOI: 10.1158/00085472.CAN-05-0259. PMID: 15930265.

16. Redaelli S., Piazza R., Rostagno R. et al. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants. J Clin Oncol 2009;27(3):469–71. DOI: 10.1200/JCO.2008.19.8853. PMID: 19075254.

17. Okabe S., Tauchi T., Tanaka Y. et al. Antileukemic activity of axitinib against cells harboring the BCR-ABL T315I point mutation. J Hematol Oncol 2015;8:97. DOI: 10.1186/s13045-015-0190-9. PMID: 26239229.

18. Anastassiadis T., Deacon S.W., Devarajan K. et al. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29(11):1039–45. DOI: 10.1038/nbt.2017. PMID: 22037377.

19. Cortes J.E., Saglio G., Kantarjian H.M. et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naive Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016;34(20):2333–40. DOI: 10.1200/JCO.2015.64.8899. PMID: 27217448.

20. Baeuerle P.A., Kufer P., Bargou R. BiTE: Teaching antibodies to engage T-cells for cancer therapy. Curr Opin Mol Ther 2009;11(1):22–30. PMID: 19169956.

21. Burki T.K. Blinatumomab significantly improves overall survival. Lancet Oncol 2017;18(4):e203. DOI: 10.1016/S14702045(17)30183-3. PMID: 28285842.

22. Patel S.B., Gojo I., Tidwell M.L. et al. Subdural hematomas in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving imatinib mesylate in conjunction with systemic and intrathecal chemotherapy. Leuk Lymphoma 2011;52(7):1211–4. DOI: 10.3109/10428194.2011.566950. PMID: 21534873.

23. Kantarjian H., Cortes J., Kim D.W. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009;113(25):6322–9. DOI: 10.1182/blood-2008-11-186817. PMID: 19369231.

24. Etienne G., Cony-Makhoul P., Mahon F.-X. Imatinib mesylate and gray hair. N Engl J Med 2002;347(6):446. DOI: 10.1056/NEJM200208083470614. PMID: 12167692.

25. Hemesath T.J., Price E.R., Takemoto C. et al. MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. Nature 1998;391(6664):298–301. DOI: 10.1038/34681. PMID: 9440696.